Velocity’s sites in Dallas, TX, and Staszów, Poland, enrolled patients in Novo Nordisk’s Phase 3 trial assessing semaglutide’s effect on participants with metabolic dysfunction–associated steatohepatitis (MASH). Trial results were published in a recent New England Journal of Medicine article detailing the GLP-1 receptor agonist’s impact on liver fibrosis.
The study found that “in patients with MASH and moderate or advanced liver fibrosis, once-weekly semaglutide at a dose of 2.4 mg improved liver histologic outcomes.”
This research marks another step toward unlocking the broader therapeutic potential of GLP-1 receptor agonists.
Read the article: https://www.nejm.org/doi/full/10.1056/NEJMoa2413258
